Literature DB >> 8606110

Burkholderia (basonym Pseudomonas) cepacia binding to lipid receptors.

F A Sylvester1, U S Sajjan, J F Forstner.   

Abstract

Piliated Burkholderia (formerly Pseudomonas) cepacia from sputa of cys tic fibrosis patients in Toronto, Canada, were shown earlier to bind to purified mucins and to a protein receptor on epithelial cells via a 22-kDa adhesin located on unique cable pili. However, a second receptor, thought to be lipid in nature, was also identified on cells and appeared to serve as the major cell receptor for poorly piliated or nonpiliated isolates. In the present study in vitro approaches were used to identify putative lipid receptors for B. cepacia and to explore the nature of the binding interaction. As judged by thin-layer chromatography overlay assays, the best receptors were digalactosylceramide and globotriosylceramide (Gb(3)). Both contain and unsubstituted terminal Gal alpha 1-4Gal sequence. B cepacia also bound moderately to galactosylceramide, gangliotriosylceramide, and gangliotetraosylceramide. Binding to glycolipids was not affected by tetramethylurea, a hydrophobic-bond-breaking adhesin for GB(3). Binding to glycolipids was not affected by tetramethylurea, a hydrophobic-bond-breaking agent. Binding was influenced by the structure of the ceramide, which probably affects the presentation of the agent. Binding was influenced by the structure of the ceramide, which probably affects the presentation of the carbohydrate epitope to the bacteria. Gb(3) was also the major receptor in lipid extracts of human erythrocytes, human buccal epithelial cells and HEp-2 laryngeal epithelial cells. In a receptor-based enzyme-linked immunosorbent assay, binding to Gb(3) within a phospholipid-cholesterol mixture (a membrane-like environment) increased and then approached saturation as a direct function of increasing bacterial concentration. The calculated value of K(a) (3.06 X 10(-8) ml/CFU), the affinity constant, was almost identical to the K(a) calculated earlier for B. cepacia binding to a set of lipid receptors in buccal epithelial cells (1.5 X 10(-8) to 2.0 X 10(-8) ml/CFU). Our findings suggest that within cell membranes, galactose-containing glycolipids, particularly Gb(3) are good candidates for receptors for B. cepacia, particularly for isolates in which cable pili are poorly expressed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606110      PMCID: PMC173935          DOI: 10.1128/iai.64.4.1420-1425.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

1.  Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A.

Authors:  B H Iglewski; J Sadoff; M J Bjorn; E S Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

2.  Specificity of binding of a strain of uropathogenic Escherichia coli to Gal alpha 1----4Gal-containing glycosphingolipids.

Authors:  K Bock; M E Breimer; A Brignole; G C Hansson; K A Karlsson; G Larson; H Leffler; B E Samuelsson; N Strömberg; C S Edén
Journal:  J Biol Chem       Date:  1985-07-15       Impact factor: 5.157

3.  Pseudomonas cepacia infection in cystic fibrosis: an emerging problem.

Authors:  A Isles; I Maclusky; M Corey; R Gold; C Prober; P Fleming; H Levison
Journal:  J Pediatr       Date:  1984-02       Impact factor: 4.406

4.  Possible role of ceramide in defining structure and function of membrane glycolipids.

Authors:  R Kannagi; E Nudelman; S Hakomori
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

5.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

6.  Carbohydrate-specific adhesion of bacteria to thin-layer chromatograms: a rationalized approach to the study of host cell glycolipid receptors.

Authors:  G C Hansson; K A Karlsson; G Larson; N Strömberg; J Thurin
Journal:  Anal Biochem       Date:  1985-04       Impact factor: 3.365

7.  Quantitative determination of the neutral glycosyl ceramides in human blood.

Authors:  D E Vance; C C Sweeley
Journal:  J Lipid Res       Date:  1967-11       Impact factor: 5.922

8.  Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers.

Authors:  U S Sajjan; L Sun; R Goldstein; J F Forstner
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

9.  Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome.

Authors:  O C Tablan; T L Chorba; D V Schidlow; J W White; K A Hardy; P H Gilligan; W M Morgan; L A Carson; W J Martone; J M Jason
Journal:  J Pediatr       Date:  1985-09       Impact factor: 4.406

10.  Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis.

Authors:  S Steinbach; L Sun; R Z Jiang; P Flume; P Gilligan; T M Egan; R Goldstein
Journal:  N Engl J Med       Date:  1994-10-13       Impact factor: 91.245

View more
  12 in total

1.  Cable pili and the 22-kilodalton adhesin are required for Burkholderia cenocepacia binding to and transmigration across the squamous epithelium.

Authors:  Teresa A Urban; Joanna B Goldberg; Janet F Forstner; Umadevi S Sajjan
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia.

Authors:  J E Hughes; J Stewart; G R Barclay; J R Govan
Journal:  Infect Immun       Date:  1997-10       Impact factor: 3.441

3.  Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.

Authors:  Lisa A Carmody; Jason J Gill; Elizabeth J Summer; Uma S Sajjan; Carlos F Gonzalez; Ryland F Young; John J LiPuma
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

4.  Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection.

Authors:  Siobhán McClean; Marc E Healy; Cassandra Collins; Stephen Carberry; Luke O'Shaughnessy; Ruth Dennehy; Áine Adams; Helen Kennelly; Jennifer M Corbett; Fiona Carty; Laura A Cahill; Máire Callaghan; Karen English; Bernard P Mahon; Sean Doyle; Minu Shinoy
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

Review 5.  Should patients with cystic fibrosis infected with Burkholderia cepacia undergo lung transplantation?

Authors:  A K Webb; J Egan
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

6.  Electrochemical characterization of globotriose-containing self-assembled monolayers on nanoporous gold and their binding of soybean agglutinin.

Authors:  Binod Pandey; Yih Horng Tan; Archana R Parameswar; Papapida Pornsuriyasak; Alexei V Demchenko; Keith J Stine
Journal:  Carbohydr Res       Date:  2012-10-13       Impact factor: 2.104

7.  Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes.

Authors:  M L Hutchison; I R Poxton; J R Govan
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

8.  Cable-piliated Burkholderia cepacia binds to cytokeratin 13 of epithelial cells.

Authors:  U S Sajjan; F A Sylvester; J F Forstner
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

Review 9.  Receptor mimicry as novel therapeutic treatment for biothreat agents.

Authors:  Richard J Thomas
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

10.  Pulmonary evolution of cystic fibrosis patients colonized by Pseudomonas aeruginosa and/or Burkholderia cepacia.

Authors:  I Jacques; J Derelle; M Weber; M Vidailhet
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.